OncoMatch/Clinical Trials/NCT05066412
Prophylactic CD45RA-depleted DLI After Haploidentical Transplantation/RIC
Is NCT05066412 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies non-drug interventions for hematologic malignancy.
To assess safety of prophylactic escaladed dose of T naïve depleted (CD45RA depleted donor lymphocyte infusion, in patients with malignant hemopathie who received an allogeneic stem cell transplant from an haplo-identical donor, after a reduced intensity conditionning regiment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Biomarker criteria
Excluded: PTPRC aberrant expression
Donor aberrant CD45RA expression due to a polymorphism in CD45 gene
Prior therapy
Must have received: haploidentical stem cell transplant after reduced-intensity conditioning
Patients who received a stem cell graft from a haploidentical donor after RIC for hematologic malignancies
Cannot have received: second allogeneic transplant
Second allogeneic transplant
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05066412 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior second allogeneic transplant disqualifies patients from enrollment.
Are patients with PTPRC alterations eligible?
No. PTPRC aberrant expression is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify